SEC Form 4 · accession 0000899243-18-029256
CytoDyn Inc. · CYDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A Klump
Director
Period of report
Nov 16, 2018
Accepted (ET)
Nov 19, 2018 · 8:01 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175680
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 16, 2018 | A | 7,034,520 | — | A | 7,034,520 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1,F2,F4 | $0.47 | Nov 16, 2018 | A | 80,822 | A | — | Aug 10, 2028 | Common Stock | 80,822 | 80,822 | D |
| Warrants (right to buy)F1,F2 | $1.35 | Nov 16, 2018 | A | 125,000 | A | Apr 26, 2016 | Apr 26, 2021 | Common Stock | 125,000 | 125,000 | D |
| Warrants (right to buy)F1,F2,F3 | $0.75 | Nov 16, 2018 | A | 1,000,000 | A | Feb 16, 2018 | Feb 16, 2023 | Common Stock | 1,000,000 | 1,000,000 | I |
| Warrants (right to buy)F1,F2,F3 | $1.00 | Nov 16, 2018 | A | 1,933,333 | A | Dec 12, 2016 | Dec 12, 2021 | Common Stock | 1,933,333 | 1,933,333 | I |
| Warrants (right to buy)F1,F2 | $1.00 | Nov 16, 2018 | A | 66,667 | A | Dec 12, 2016 | Dec 12, 2021 | Common Stock | 66,667 | 66,667 | I |
Explanation of responses
- F1On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.
- F2In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).
- F3The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein.
- F4The options (including predecessor options) vested with respect to 5,822 shares on September 1, 2018, and the remaining shares vest in three equal quarterly installments commencing on December 1, 2018.